Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Progress and prospects for blood-stage malaria vaccines.

Miura K.

Expert Rev Vaccines. 2016 Jun;15(6):765-81. doi: 10.1586/14760584.2016.1141680. Epub 2016 Feb 3.

2.

Insights into the Immunological Properties of Intrinsically Disordered Malaria Proteins Using Proteome Scale Predictions.

Guy AJ, Irani V, MacRaild CA, Anders RF, Norton RS, Beeson JG, Richards JS, Ramsland PA.

PLoS One. 2015 Oct 29;10(10):e0141729. doi: 10.1371/journal.pone.0141729. eCollection 2015.

3.

The effect of daily co-trimoxazole prophylaxis on natural development of antibody-mediated immunity against P. falciparum malaria infection in HIV-exposed uninfected Malawian children.

Longwe H, Jambo KC, Phiri KS, Mbeye N, Gondwe T, Hall T, Tetteh KK, Drakeley C, Mandala WL.

PLoS One. 2015 Mar 25;10(3):e0121643. doi: 10.1371/journal.pone.0121643. eCollection 2015.

4.

Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.

Shimp RL Jr, Rowe C, Reiter K, Chen B, Nguyen V, Aebig J, Rausch KM, Kumar K, Wu Y, Jin AJ, Jones DS, Narum DL.

Vaccine. 2013 Jun 19;31(28):2954-62. doi: 10.1016/j.vaccine.2013.04.034. Epub 2013 Apr 24.

5.

Identification of VAR2CSA domain-specific inhibitory antibodies of the Plasmodium falciparum erythrocyte membrane protein 1 using a novel flow cytometry assay.

Obiakor H, Avril M, Macdonald NJ, Srinivasan P, Reiter K, Anderson C, Holmes KL, Fried M, Duffy PE, Smith JD, Narum DL, Miller LH.

Clin Vaccine Immunol. 2013 Mar;20(3):433-42. doi: 10.1128/CVI.00638-12. Epub 2013 Jan 23.

6.

Analysis of the conformation and function of the Plasmodium falciparum merozoite proteins MTRAP and PTRAMP.

Uchime O, Herrera R, Reiter K, Kotova S, Shimp RL Jr, Miura K, Jones D, Lebowitz J, Ambroggio X, Hurt DE, Jin AJ, Long C, Miller LH, Narum DL.

Eukaryot Cell. 2012 May;11(5):615-25. doi: 10.1128/EC.00039-12. Epub 2012 Mar 30.

7.

Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.

Imam M, Devi YS, Verma AK, Chauhan VS.

Clin Vaccine Immunol. 2011 Aug;18(8):1221-8. doi: 10.1128/CVI.00064-11. Epub 2011 Jun 1.

8.

Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic.

Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, Lanar DE, Dutta S, Rosenthal PJ, Dorsey G, John CC.

J Infect Dis. 2011 Jul 1;204(1):19-26. doi: 10.1093/infdis/jir223.

9.

Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children.

Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, Mwacharo J, Vekemans J, Njuguna P, Leach A, Lievens M, Dutta S, von Seidlein L, Savarese B, Villafana T, Lemnge MM, Cohen J, Marsh K, Corran PH, Angov E, Riley EM, Drakeley CJ.

J Infect Dis. 2011 Jul 1;204(1):9-18. doi: 10.1093/infdis/jir222.

10.

Effect of HIV infection on the acute antibody response to malaria antigens in children: an observational study.

Muema DK, Ndungu FM, Kinyanjui SM, Berkley JA.

Malar J. 2011 Mar 5;10:55. doi: 10.1186/1475-2875-10-55.

11.

Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate.

Plassmeyer ML, Reiter K, Shimp RL Jr, Kotova S, Smith PD, Hurt DE, House B, Zou X, Zhang Y, Hickman M, Uchime O, Herrera R, Nguyen V, Glen J, Lebowitz J, Jin AJ, Miller LH, MacDonald NJ, Wu Y, Narum DL.

J Biol Chem. 2009 Sep 25;284(39):26951-63. doi: 10.1074/jbc.M109.013706. Epub 2009 Jul 24.

Supplemental Content

Support Center